Startseite > Aktien > BIOSENIC > Nachrichten
    BIOSENIC Aktie
    Aktie
    ISIN: BE0974280126 WKN: A14NHV Land Flagge BE Belgien
    Zur Watchlist hinzufügenZur Watchlist hinzufügen Zum Portfolio hinzufügenZum Portfolio hinzufügen
    0,0041
     
    EUR
    0,00 %
    Letzter Kurs 16:18:26 Lang & Schwarz
    Geldkurs
    16:18:26
    0,0011
     
    EUR
    909.091 STK
    Briefkurs
    16:18:26
    0,0071
     
    EUR
    909.091 STK

    BIOSENIC Aktie kaufen

    Kauf
    Verkauf

    Neueste Nachrichten

    BioSenic S.A.: Transparency notification received from ABO Infinium Americas OpCo LTD.
    07.10.24 · globenewswire · BIOSENICEnglische Nachricht
    BioSenic announces that it has started to look for new assets, the securing of its financing for the coming months by means of an amendment to its convertible bond contract, a change to the composition of its board of directors
    30.09.24 · globenewswire · BIOSENICEnglische Nachricht
    BioSenic reports half year 2024 results
    30.09.24 · globenewswire · BIOSENICEnglische Nachricht
    Véronique Pomi-Schneiter stands down as BioSenic's Deputy CEO
    17.09.24 · globenewswire · BIOSENICEnglische Nachricht
    BioSenic S.A.: Transparency notification received from ABO Infinium Americas OpCo LTD.  
    19.08.24 · globenewswire · BIOSENICEnglische Nachricht
    Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in relapsing-remitting multiple sclerosis
    14.08.24 · globenewswire · BIOSENICEnglische Nachricht
    Medsenic/BioSenic patent granted in Japan for more protection of its therapeutic platform
    13.08.24 · globenewswire · BIOSENICEnglische Nachricht
    BioSenic S.A.: Transparency notification received from ABO Infinium Americas OpCo LTD.
    13.08.24 · globenewswire · BIOSENICEnglische Nachricht
    BioSenic S.A.: Transparency notification received from Mr François Rieger
    19.07.24 · globenewswire · BIOSENICEnglische Nachricht
    BioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of arsenic trioxide (ATO) targeting cGvHD
    18.07.24 · globenewswire · BIOSENICEnglische Nachricht
    BioSenic S.A.: Transparency notification received from Véronique Pomi  
    12.07.24 · globenewswire · BIOSENICEnglische Nachricht
    Medsenic, subsidiary of BioSenic SA, extends key patent to the United States
    05.07.24 · globenewswire · BIOSENICEnglische Nachricht